How Mushroom Companies Navigate FDA and FTC Restrictions

Mushroom Supplement Regulation

30 days to notify FDA

Before marketing a product with a structure/function health claim, supplement companies must notify the FDA at least 30 days in advance. This notification requires only a description of the intended claim — it does not involve evidence review or approval of any kind.

Bailey et al., Critical Reviews in Food Science and Nutrition, 2020

Post-market only

FDA's enforcement model acts after the fact — products can be sold before FDA reviews safety or claim accuracy (Li et al., Innovations in Pharmacy, 2023)

Significant variation

Multiple commercial Chaga supplements tested in 2025 showed significant variation in bioactive content — evidence many companies don't comply correctly (Windsor et al., IJMS, 2025)

6 core strategies

structure/function claims, disclaimers, substantiation files, educational content, cGMP certification, and third-party testing constitute the compliance toolkit

Bailey et al., Critical Reviews in Food Science and Nutrition, 2020

View as image ↗

Selling a mushroom supplement in the US is legal. Claiming it "treats" or "cures" any disease is not. Between those two points lies a compliance framework that every company marketing reishi, lion's mane, or turkey tail must navigate — a combination of FDA labeling rules and FTC advertising standards that define what can be said, what requires evidence, and what is prohibited outright.

The framework is more permissive than most consumers realize, and more complex than most companies handle correctly. Under the DSHEA framework, mushroom supplements require no pre-market approval for safety or efficacy. Companies are responsible for ensuring their products are safe and their claims are accurate — but they make this determination themselves. FDA enters the picture after the fact.

This means the quality of the mushroom supplement market is largely a function of how seriously individual companies take their compliance obligations, and how consistently the regulatory environment enforces those obligations when companies do not.

How the FDA-FTC Regulatory Split Works

Two federal agencies share jurisdiction over mushroom supplement marketing. They cover different aspects of what a company communicates about its products.

The FDA regulates product labeling — the text on the package, the product insert, and the company's direct product pages. Under DSHEA, the FDA requires that label claims be substantiated, that certain categories of claims require specific notification or approval, and that specified disclaimer language appear on products making structure/function claims. The FDA enforces these requirements after products are on the market through warning letters, recall requests, and occasionally injunctions.

The FTC regulates advertising — marketing that extends beyond the product label to include digital advertising, social media, influencer marketing, email campaigns, and website content that goes beyond pure product description. The FTC requires that advertising claims be truthful and substantiated, and its 2022 Health Products Compliance Guidance (replacing the 1998 version) updated its substantiation standard for disease-benefit claims to generally require evidence from randomized controlled trials.

The two agencies coordinate through a Memorandum of Understanding and frequently send joint warning letters when a company's combined product claims and advertising practices appear to violate both sets of rules simultaneously.

A comprehensive 2020 review by Bailey and colleagues mapped the DSHEA regulatory structure in detail, distinguishing the three types of claims available to supplement companies and the different evidence and procedural requirements for each.^[1]

The Six Compliance Strategies Mushroom Companies Use

Compliant mushroom supplement companies navigate FDA and FTC restrictions through a combination of claim-type selection, procedural compliance, and proactive quality signaling. Six strategies constitute the practical compliance toolkit:

1. Structure/function claims with 30-day FDA notification. Choose claim language that describes the product's effect on normal body function rather than any disease state. Submit notification to FDA at least 30 days before first marketing the claim. Maintain documentation of the evidence supporting the claim.

2. Mandatory disclaimer placement. Any product carrying a structure/function claim must bear this exact language: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." FDA regulations specify the font size (no smaller than one-sixteenth inch), location (immediate vicinity of the claim), and that it appear with equal prominence to the claim.

3. Substantiation file maintenance. Companies must be able to demonstrate, if FDA requests, that their claims are supported by "competent and reliable scientific evidence." This evidence does not need to be submitted to FDA before marketing, but it must exist and be available. A substantiation file documents the studies and data underlying each claim.

4. Educational content marketing as a claim-free alternative. Rather than making health claims, many companies publish scientific overviews, research summaries, and educational content about the bioactives in their products. Educational content about beta-glucans, for example, can reference published research without making a product-specific claim. This approach builds consumer trust while keeping the brand in compliance.

5. cGMP certification as a consumer trust signal. FDA's Current Good Manufacturing Practice regulations for dietary supplements require specific facility standards, testing protocols, batch records, and quality control procedures. Voluntary third-party cGMP audits and certifications (NSF International, USP, Eurofins) provide evidence that a company's manufacturing processes meet these standards, which is a meaningful compliance signal.

6. Third-party testing and certificates of analysis. Independent testing of finished products for claimed bioactives (beta-glucan percentage, specific compounds) and contaminants (heavy metals, pesticides, microbial contamination) provides documentation that the product contains what is claimed. Public availability of COAs is not required by law but has become an industry quality signal.

Structure/Function Claims in Depth: What the 30-Day System Actually Requires

Structure/function claims are the primary vehicle for health communication in mushroom supplements, and they are narrower than many companies treat them.^[1]

A structure/function claim must describe the role of a nutrient or dietary ingredient in affecting a normal structure or function of the body — not the prevention, treatment, mitigation, or cure of any disease. The legal line between "supports immune function" and "boosts immunity to fight infection" is not merely semantic. The first describes a normal body function; the second implies action against a pathogen (a disease context).

The 30-day notification requirement is frequently misunderstood by consumers as a form of approval. It is not. Companies submit a notification stating what claim they intend to make. FDA does not respond to these notifications with approval or denial; they go into a database. If the claim later appears to violate the rules, FDA can act. The notification requirement exists to give FDA advance visibility, not to create a pre-market review gate.

The substantiation standard for structure/function claims — "competent and reliable scientific evidence" — allows for a range of evidence types including observational studies, mechanistic research, and expert opinion. This is deliberately lower than the "significant scientific agreement" standard required for FDA-authorized health claims (which require extensive pre-market review) or the "randomized controlled trial" standard now generally expected by FTC for disease-benefit claims in advertising.

A company can therefore legally say "supports immune function" on its label based on preclinical evidence and mechanistic research, while being unable to make the same claim in digital advertising without an RCT backing it under the FTC standard. The regulatory requirements for the same information can differ depending on where it appears.

The Substantiation File: How Companies Document Their Evidence

The substantiation file is the internal compliance document most consumers have never heard of and that distinguishes companies taking their compliance obligations seriously from those that are not.

For each structure/function claim on a product, a company should maintain documentation covering: the studies they considered when developing the claim, why they determined the evidence met the "competent and reliable" standard, how the claim language was developed, and what limitations in the evidence they considered. This file is not submitted to FDA; it is held internally and should be available if FDA investigates a complaint or initiates an inspection.

The Bailey 2020 review confirmed that FDA can request to review a company's substantiation during an inspection, and the absence of adequate substantiation is itself a compliance violation — even if the claim language on the label appears superficially acceptable.^[1]

In practice, many companies operate without substantiation files, or maintain files that would not survive regulatory scrutiny. This is particularly common in the mushroom supplement category, where some companies import products from overseas suppliers and apply health claims based on general category reputation rather than product-specific testing and evidence review.

Educational Content Marketing as a Claim-Free Alternative

The most sophisticated compliance strategy in the mushroom supplement industry is the use of educational content that communicates the science without triggering the claim rules.

A company can publish a scientifically accurate article about beta-glucan research and its effects on immune cell activity. That article can cite peer-reviewed studies. It can link from the company's website. It can describe biological mechanisms in detail. What it cannot do is make a direct product claim — a connection between a specific product and a specific health outcome in a way that would trigger the claim rules.

The phrase "supports immune function" on a supplement label triggers the 30-day notification and disclaimer requirements. An educational page explaining how beta-glucans interact with Dectin-1 receptors on immune cells, citing the underlying research, generally does not — provided it is clearly educational in nature and not a disguised product claim.

This distinction matters for consumers evaluating companies. A company that invests in genuine scientific education, cites primary research, and acknowledges evidence limitations is demonstrating a different orientation than one that makes broad health claims based on minimal substantiation.

Where Many Companies Still Get It Wrong

The compliance framework described above is theoretically clear. In practice, many mushroom supplement companies navigate it poorly.

A 2023 narrative review by Li and colleagues documented that FDA's approach to dietary supplement enforcement is inadequate for preventing consumer harm — adverse event underreporting, weak enforcement mechanisms, and the post-market-only model create systemic gaps that allow non-compliant products to remain on shelves for extended periods.^[2]

Quality testing data corroborates this. An analysis of commercial Ganoderma lucidum supplements in the US market by Wu and colleagues found major quality inconsistencies across products — significant variation in beta-glucan and other bioactive content that cannot exist if GMP compliance and proper product testing are being maintained.^[3] A 2025 comparative analysis of commercial Chaga supplements by Windsor and colleagues found significant variation in bioactive compound content across brands, again reflecting inadequate quality control rather than systematic compliance.^[4]

The pattern in both analyses is that the regulatory system creates requirements but does not reliably enforce them. A company that does not maintain accurate substantiation, does not test its finished products, and makes claims that exceed what the evidence supports may operate for years without enforcement action.

This is the practical reality that consumers need to understand. The six compliance strategies described in this article exist and are required by law. But the enforcement mechanism that would guarantee all companies follow them is limited and post-market in nature. Buyers cannot rely on regulatory compliance as a proxy for product quality — they need to verify quality directly through available signals like published COAs, cGMP certification, and third-party beta-glucan testing results. For guidance on reading supplement labels in this context, see FDA and Mushroom Supplements: How DSHEA Shapes What Companies Can (and Can't) Say and FDA Warning Letters to Mushroom Companies: What Gets Flagged.

For how the EU approaches the same problem with pre-market authorization requirements, see EU Novel Food Regulations and Mushroom Supplements, and for the practical consumer quality signals, see Mushroom Supplement Adulteration: How Widespread Is the Problem?.

The Bottom Line

Mushroom supplement companies navigate FDA and FTC restrictions primarily through structure/function claim selection (with mandatory 30-day FDA notification and required disclaimer language), substantiation file maintenance, and cGMP compliance — complemented by educational content marketing and third-party testing as consumer trust signals. FDA's post-market enforcement model means products can reach and remain on shelves even when non-compliant; quality analyses of commercial Ganoderma and Chaga supplements confirm that many companies fail to navigate these requirements correctly. The six-strategy compliance framework exists in law; consistent enforcement of it does not.

Frequently Asked Questions

How do supplement companies stay compliant with the FDA?

Under DSHEA, mushroom supplement companies stay compliant by: selecting structure/function claim language that describes normal body function rather than disease treatment; submitting 30-day notification to FDA before marketing each claim; placing the mandatory disclaimer on the product; maintaining a substantiation file of supporting evidence; following cGMP manufacturing standards; and ensuring product testing confirms the label claims. Pre-market FDA approval is not required for most supplement claims, which means compliance is largely self-managed.

How do mushroom companies market their products legally?

Mushroom companies can legally market products using structure/function claims ("supports immune function," "promotes cognitive health") with a 30-day FDA notification and the FDA disclaimer. They can also publish educational content about the science of mushroom bioactives without making product-specific health claims. What they cannot do is claim their product treats, cures, or prevents any specific disease — including cancer, Alzheimer's, or diabetes — either on the label or in advertising without crossing into FDA/FTC violation territory.

What is the DSHEA compliance checklist for supplement companies?

Core DSHEA compliance requirements include: (1) ensure the product is safe and manufactured under cGMP conditions; (2) for structure/function claims, submit 30-day notification to FDA and include the required disclaimer; (3) maintain a substantiation file documenting the evidence behind each claim; (4) avoid disease claims (prohibited without FDA health claim authorization); (5) keep New Dietary Ingredient notifications for any ingredient not marketed in supplements before 1994; (6) maintain records adequate for FDA inspection. FTC additionally requires that advertising claims be substantiated with competent and reliable scientific evidence.

How do mushroom companies use science without making health claims?

Many companies publish educational content explaining the science of mushroom bioactives — describing how beta-glucans interact with immune cell receptors, or what research on cordycepin shows in preclinical models — without making direct claims about their products. This educational approach communicates the underlying research to consumers while remaining separate from the product claim framework that triggers FDA/FTC requirements. The content must be genuinely educational in nature; if the surrounding context makes it function as an implied product claim, it may still be treated as advertising.

What is the role of a substantiation file for supplement claims?

A substantiation file is the internal documentation supporting each structure/function claim on a supplement product. It typically includes the studies considered when developing the claim, the company's assessment of why that evidence meets the "competent and reliable scientific evidence" standard, the claim language development process, and any identified evidence limitations. This file is not submitted to FDA before marketing; it is maintained internally and must be available if FDA requests it during an inspection. Its absence or inadequacy is a compliance violation even if the label language is otherwise acceptable.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.